Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 333

1.

Association of Serum Folate Levels With Cardiovascular Mortality Among Adults With Rheumatoid Arthritis.

Sonawane K, Zhu Y, Chan W, Aguilar D, Deshmukh AA, Suarez-Almazor ME.

JAMA Netw Open. 2020 Feb 5;3(2):e200100. doi: 10.1001/jamanetworkopen.2020.0100.

2.

Interactions and perceptions of patients with rheumatoid arthritis participating in an online support group.

des Bordes JKA, Foreman J, Westrich-Robertson T, Lopez-Olivo MA, Peterson SK, Hofstetter C, Lyddiatt A, Willcockson I, Leong A, Suarez-Almazor ME.

Clin Rheumatol. 2020 Jan 31. doi: 10.1007/s10067-020-04967-y. [Epub ahead of print]

PMID:
32006180
3.

Outcomes Reported in Prospective Long-Term Observational Studies and Registries of Patients with Rheumatoid Arthritis Worldwide: An OMERACT Systematic Review.

Lopez-Olivo MA, Zogala RJ, des Bordes J, Zamora NV, Christensen R, Rai D, Goel N, Carmona L, Pratt G, Strand V, Suarez-Almazor ME.

Arthritis Care Res (Hoboken). 2020 Jan 31. doi: 10.1002/acr.24163. [Epub ahead of print]

PMID:
32004421
4.

Knowledge, beliefs, and concerns about bone health from a systematic review and metasynthesis of qualitative studies.

des Bordes J, Prasad S, Pratt G, Suarez-Almazor ME, Lopez-Olivo MA.

PLoS One. 2020 Jan 15;15(1):e0227765. doi: 10.1371/journal.pone.0227765. eCollection 2020.

5.

Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer.

Pundole X, Zamora NV, Siddhanamatha H, Lin H, Tayar J, Hong LC, Li L, Suarez-Almazor ME.

Clin Rheumatol. 2020 Mar;39(3):787-794. doi: 10.1007/s10067-019-04874-x. Epub 2019 Dec 18.

PMID:
31853733
6.

Comparison of multimedia and printed patient education tools for patients with osteoporosis: a 6-month randomized controlled trial.

Lopez-Olivo MA, des Bordes JKA, Lin H, Rizvi T, Volk RJ, Suarez-Almazor ME.

Osteoporos Int. 2019 Dec 16. doi: 10.1007/s00198-019-05210-4. [Epub ahead of print]

PMID:
31844906
7.

Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.

Abdel-Wahab N, Suarez-Almazor ME.

Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii40-vii48. doi: 10.1093/rheumatology/kez297.

8.

Real-World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis.

Michaud K, Vrijens B, Tousset E, Pedro S, Schumacher R, Dasic G, Chen C, Agarwal E, Suarez-Almazor ME.

ACR Open Rheumatol. 2019 Sep 6;1(9):560-570. doi: 10.1002/acr2.11079. eCollection 2019 Nov.

9.

Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.

Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, Tummala S, Woodman K, Abdel-Wahab N, Diab A.

J Immunother Cancer. 2019 Nov 21;7(1):319. doi: 10.1186/s40425-019-0774-y.

10.

Evidence that Swimming May Be Protective of Knee Osteoarthritis: Data from the Osteoarthritis Initiative.

Lo GH, Ikpeama UE, Driban JB, Kriska AM, McAlindon TE, Petersen NJ, Storti KL, Eaton CB, Hochberg MC, Jackson RD, Kwoh CK, Nevitt MC, Suarez-Almazor ME.

PM R. 2019 Oct 19. doi: 10.1002/pmrj.12267. [Epub ahead of print]

PMID:
31628825
11.

Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR).

Ramos-Casals M, Maria A, Suárez-Almazor ME, Lambotte O, Fisher BA, Hernández-Molina G, Guilpain P, Pundole X, Flores-Chávez A, Baldini C, Bingham Iii CO, Brito-Zerón P, Gottenberg JE, Kostine M, Radstake TRD, Schaeverbeke T, Schulze-Koops H, Calabrese L, Khamashta MA, Mariette X; ICIR.

Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):114-122. Epub 2019 Aug 28.

12.

Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer?

Buckley LM, Suarez-Almazor ME.

Arthritis Rheumatol. 2019 Dec;71(12):1971-1973. doi: 10.1002/art.41064. Epub 2019 Oct 23. No abstract available.

PMID:
31379056
14.

Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.

Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, Lin H, Wong MK, Abdelrahim M, Gaber AO, Suarez-Almazor ME, Diab A.

J Immunother Cancer. 2019 Jun 24;7(1):158. doi: 10.1186/s40425-019-0639-4.

15.

A comprehensive scoping review to identify standards for the development of health information resources on the internet.

Abdel-Wahab N, Rai D, Siddhanamatha H, Dodeja A, Suarez-Almazor ME, Lopez-Olivo MA.

PLoS One. 2019 Jun 20;14(6):e0218342. doi: 10.1371/journal.pone.0218342. eCollection 2019.

16.

Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare.

Kim ST, Bittar M, Kim HJ, Neelapu SS, Zurita AJ, Nurieva R, Suarez-Almazor ME.

J Immunother Cancer. 2019 May 14;7(1):126. doi: 10.1186/s40425-019-0597-x.

17.

Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial.

Singh JA, Fraenkel L, Green C, Alarcón GS, Barton JL, Saag KG, Hanrahan LM, Raymond SC, Kimberly RP, Leong AL, Reyes E, Street RL Jr, Suarez-Almazor ME, Eakin GS, Marrow L, Morgan CJ, Caro B, Sloan JA, Jandali B, Garcia SR, Grossman J, Winthrop KL, Trupin L, Dall'Era M, Meara A, Rizvi T, Chatham WW, Yazdany J.

PLoS Med. 2019 May 8;16(5):e1002800. doi: 10.1371/journal.pmed.1002800. eCollection 2019 May.

18.

Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials.

Klokker L, Berthelsen DB, Woodworth T, Andersen KM, Furst DE, Devoe D, Williamson PR, Suarez-Almazor ME, Strand V, Leong AL, Goel N, Boers M, Brooks PM, March L, Sloan VS, Tugwell P, Simon LS, Christensen R.

J Rheumatol. 2019 Sep;46(9):1173-1178. doi: 10.3899/jrheum.190196. Epub 2019 May 1.

PMID:
31043547
19.

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.

Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, Lin H, Wong MK, Abdelrahim M, Gaber AO, Suarez-Almazor ME, Diab A.

J Immunother Cancer. 2019 Apr 16;7(1):106. doi: 10.1186/s40425-019-0585-1. Erratum in: J Immunother Cancer. 2019 Jun 24;7(1):158.

20.

Digital Patient Education and Decision Aids.

Lopez-Olivo MA, Suarez-Almazor ME.

Rheum Dis Clin North Am. 2019 May;45(2):245-256. doi: 10.1016/j.rdc.2019.01.001. Epub 2019 Mar 8. Review.

PMID:
30952396
21.

Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy.

Hwang JP, Huang D, Vierling JM, Suarez-Almazor ME, Shih YT, Chavez-MacGregor M, Duan Z, Giordano SH, Hershman DL, Fisch MJ, Cantor SB.

JCO Clin Cancer Inform. 2019 Mar;3:1-12. doi: 10.1200/CCI.18.00097.

22.

Arthritis risk with immune checkpoint inhibitor therapy for cancer.

Pundole X, Abdel-Wahab N, Suarez-Almazor ME.

Curr Opin Rheumatol. 2019 May;31(3):293-299. doi: 10.1097/BOR.0000000000000601.

PMID:
30870217
23.

Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis.

Lopez-Olivo MA, Negrón JB, Zogala RJ, Carmona L, Criner K, Goel N, Gonzalez-Lopez L, Ingegnoli F, Leong A, March L, Shea B, Strand V, Tugwell P, Westrich-Robertson T, Zamora NV, Christensen R, Suarez-Almazor ME.

J Rheumatol. 2019 Sep;46(9):1164-1167. doi: 10.3899/jrheum.181076. Epub 2019 Mar 1.

PMID:
30824644
24.

Systematic Review of Recommendations on the Use of Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer.

Lopez-Olivo MA, Colmegna I, Karpes Matusevich AR, Qi SR, Zamora NV, Sharma R, Pratt G, Suarez-Almazor ME.

Arthritis Care Res (Hoboken). 2020 Mar;72(3):309-318. doi: 10.1002/acr.23865.

PMID:
30821928
25.

Systematic Review of Economic Evaluations of Cycling Versus Swapping Medications in Patients With Rheumatoid Arthritis After Failure to Respond to Tumor Necrosis Factor Inhibitors.

Karpes Matusevich AR, Suarez-Almazor ME, Cantor SB, Lal LS, Swint JM, Lopez-Olivo MA.

Arthritis Care Res (Hoboken). 2020 Mar;72(3):343-352. doi: 10.1002/acr.23859.

PMID:
30801951
26.

OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions.

Toupin-April K, Barton JL, Fraenkel L, Meara A, Li LC, Brooks P, de Wit M, Stacey D, Légaré F, Shea B, Lyddiatt A, Hofstetter C, Christensen R, Scholte Voshaar M, Suarez-Almazor ME, Boonen A, Meade T, March L, Jull JE, Campbell W, Alten R, Karuranga S, Morgan EM, Kelly A, Kaufman J, Hill S, Maxwell LJ, Beaton D, El-Miedany Y, Mittoo S, Bartlett SJ, Singh JA, Tugwell PS.

J Rheumatol. 2019 Oct;46(10):1409-1414. doi: 10.3899/jrheum.181071. Epub 2019 Feb 1.

27.

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience.

Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A.

J Immunother Cancer. 2019 Jan 6;7(1):2. doi: 10.1186/s40425-018-0478-8.

28.

Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists.

Kim ST, Suarez-Almazor ME.

Expert Rev Clin Immunol. 2019 Mar;15(3):211-213. doi: 10.1080/1744666X.2019.1559731. Epub 2018 Dec 27. No abstract available.

PMID:
30589372
29.

Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials.

Tarp S, Jørgensen TS, Furst DE, Dossing A, Taylor PC, Choy EH, Suarez-Almazor ME, Lyddiatt A, Kristensen LE, Bliddal H, Christensen R.

Semin Arthritis Rheum. 2019 Jun;48(6):958-966. doi: 10.1016/j.semarthrit.2018.10.002. Epub 2018 Oct 9.

PMID:
30396592
30.

Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review.

Lu H, Lok AS, Warneke CL, Ahmed S, Torres HA, Martinez F, Suarez-Almazor ME, Foreman JT, Ferrajoli A, Hwang JP.

Lancet Haematol. 2018 Oct;5(10):e474-e478. doi: 10.1016/S2352-3026(18)30152-2.

31.

Reply to D.L. Kimpel et al.

Suarez-Almazor ME, Thompson JA, Brahmer JR.

J Clin Oncol. 2018 Sep 10;36(26):2744. doi: 10.1200/JCO.2018.79.1798. Epub 2018 Jul 18. No abstract available.

PMID:
30020818
32.

Factors associated with the orthopaedic surgeon's decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1905 patients.

Huynh C, Puyraimond-Zemmour D, Maillefert JF, Conaghan PG, Davis AM, Gunther KP, Hawker G, Hochberg MC, Kloppenburg M, Lim K, Lohmander LS, Mahomed NN, March L, Pavelka K, Punzi L, Roos EM, Sanchez-Riera L, Singh JA, Suarez-Almazor ME, Dougados M, Gossec L.

Osteoarthritis Cartilage. 2018 Oct;26(10):1311-1318. doi: 10.1016/j.joca.2018.06.013. Epub 2018 Jul 11.

33.

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease.

Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME.

Ann Intern Med. 2018 Jul 17;169(2):133-134. doi: 10.7326/L18-0209. No abstract available.

PMID:
30014109
34.

Myositis as an adverse event of immune checkpoint blockade for cancer therapy.

Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME.

Semin Arthritis Rheum. 2019 Feb;48(4):736-740. doi: 10.1016/j.semarthrit.2018.05.006. Epub 2018 May 18.

PMID:
29909921
35.

Running does not increase symptoms or structural progression in people with knee osteoarthritis: data from the osteoarthritis initiative.

Lo GH, Musa SM, Driban JB, Kriska AM, McAlindon TE, Souza RB, Petersen NJ, Storti KL, Eaton CB, Hochberg MC, Jackson RD, Kwoh CK, Nevitt MC, Suarez-Almazor ME.

Clin Rheumatol. 2018 Sep;37(9):2497-2504. doi: 10.1007/s10067-018-4121-3. Epub 2018 May 4.

36.

Training in patient-centered outcomes research for specific researcher communities.

Landsittel DP, Kessler L, Schmid CH, Marantz P, Suarez-Almazor ME.

J Clin Transl Sci. 2017 Oct;1(5):278-284. doi: 10.1017/cts.2017.307.

37.

Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol.

Kelly A, Tong A, Tymms K, March L, Craig JC, De Vera M, Evans V, Hassett G, Toupin-April K, van den Bemt B, Teixeira-Pinto A, Alten R, Bartlett SJ, Campbell W, Dawson T, Gill M, Hebing R, Meara A, Nieuwlaat R, Shaw Y, Singh JA, Suarez-Almazor M, Sumpton D, Wong P, Christensen R, Beaton D, de Wit M, Tugwell P; OMERACT-Adherence Group.

Trials. 2018 Mar 27;19(1):204. doi: 10.1186/s13063-018-2565-z.

38.

Assessing information needs and use of online resources for disease self-management in patients with rheumatoid arthritis: a qualitative study.

des Bordes JKA, Gonzalez E, Lopez-Olivo MA, Shethia M, Nayak P, Suarez-Almazor ME.

Clin Rheumatol. 2018 Jul;37(7):1791-1797. doi: 10.1007/s10067-018-4047-9. Epub 2018 Mar 2.

PMID:
29500557
39.

Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study.

Hwang JP, Lok AS, Fisch MJ, Cantor SB, Barbo A, Lin HY, Foreman JT, Vierling JM, Torres HA, Granwehr BP, Miller E, Eng C, Simon GR, Ahmed S, Ferrajoli A, Romaguera J, Suarez-Almazor ME.

J Clin Oncol. 2018 Feb 15:JCO2017756387. doi: 10.1200/JCO.2017.75.6387. [Epub ahead of print]

PMID:
29447061
40.

Readmission Patterns After GI Cancer Hospitalizations: The Medical Versus Surgical Patient.

Manzano JM, Yang M, Zhao H, Elting LS, George MC, Luo R, Suarez-Almazor ME.

J Oncol Pract. 2018 Mar;14(3):e137-e148. doi: 10.1200/JOP.2017.026310. Epub 2018 Feb 13.

41.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network.

J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.

42.

Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant.

Hwang JP, Ahmed S, Ariza-Heredia EJ, Duan Z, Zhao H, Schmeler KM, Ramondetta L, Parker SL, Suarez-Almazor ME, Ferrajoli A, Shih YT, Giordano SH, Chiao EY.

Biol Blood Marrow Transplant. 2018 May;24(5):1094-1098. doi: 10.1016/j.bbmt.2018.01.019. Epub 2018 Feb 9.

43.

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.

Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME.

Ann Intern Med. 2018 Jan 16;168(2):121-130. doi: 10.7326/M17-2073. Epub 2018 Jan 2.

PMID:
29297009
44.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.

J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.

45.

Treating Early Undifferentiated Arthritis: A Systematic Review and Meta-Analysis of Direct and Indirect Trial Evidence.

Lopez-Olivo MA, Kakpovbia-Eshareturi V, des Bordes JK, Barbo A, Christensen R, Suarez-Almazor ME.

Arthritis Care Res (Hoboken). 2018 Sep;70(9):1355-1365. doi: 10.1002/acr.23474. Epub 2018 Jul 5.

46.

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.

Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A.

Invest New Drugs. 2018 Aug;36(4):638-646. doi: 10.1007/s10637-017-0534-0. Epub 2017 Nov 21.

47.

Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.

Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing A.

Invest New Drugs. 2018 Aug;36(4):601-607. doi: 10.1007/s10637-017-0524-2. Epub 2017 Oct 27.

48.

Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis.

Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME.

Lupus. 2018 Apr;27(4):572-583. doi: 10.1177/0961203317731532. Epub 2017 Sep 24. Review.

PMID:
28945149
49.

Online Educational Tool to Promote Bone Health in Cancer Survivors.

des Bordes JKA, Suarez-Almazor ME, Volk RJ, Lu H, Edwards B, Lopez-Olivo MA.

J Health Commun. 2017 Oct;22(10):808-817. doi: 10.1080/10810730.2017.1360415. Epub 2017 Sep 18.

PMID:
28922062
50.

Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.

Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, Johnson DH, Uemura M, Diab A.

Ann Rheum Dis. 2017 Dec;76(12):2061-2064. doi: 10.1136/annrheumdis-2017-211560. Epub 2017 Aug 22.

PMID:
28830882

Supplemental Content

Loading ...
Support Center